BackAligos Therapeutics Overview
Aligos Therapeutics Inc

Aligos Therapeutics Target Price

See Aligos Therapeutics's analyst price targets ($20) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$5.59

Average Target Price

$20.00257.8% upside

1 analysts in the last 4 months

High: $20 | Low: $20

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-21Cantor Fitzgerald$20257.8% upsideOpen
2026-01-07UBSMichael Yee$20257.8% upsideOpen
2023-01-06Piper Sandler$346.3% downsideOpen
2023-01-06Jefferies$346.3% downsideOpen

Aligos Therapeutics (ALGS) FAQ

As of the most recent data, ALGS shows a target price of $20. Scroll down for historical charts and peer comparison views.

If Aligos Therapeutics moved to the average analyst target of $20, shares would be roughly 257.8% higher than $5.59. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Aligos Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has Aligos Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $20) with ownership activity and broader fundamentals.

Aligos Therapeutics's target price is $20; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.